Form 4: Zynex COO Receives Significant Restricted Stock Award, Reports Tax Withholding

Zynex Inc.'s Chief Operating Officer, Anna Lucsok, reported the grant of 7,500 restricted stock units and the withholding of shares for tax obligations.

Summary

• Anna Lucsok, Chief Operating Officer of Zynex Inc. (ZYXI), reported changes in her beneficial ownership of company stock.
• On July 27, 2025, Ms. Lucsok was granted 7,500 shares of Common Stock as a Restricted Stock Award (RSA) under the Issuer's 2017 Stock Incentive Plan.
• These 7,500 RSA shares will vest equally on an annual basis over a four-year period, commencing one year from the grant date.
• Following this award, Ms. Lucsok's total unvested restricted stock awards under the Plan amount to 64,412 shares.
• On July 28, 2025, 3,793 shares of Common Stock were withheld by Zynex Inc. at a price of $2.56 per share.
• This withholding was to satisfy income tax withholding and remittance obligations in connection with the net settlement of Restricted Stock Awards and does not represent a sale.
• After the tax withholding, Ms. Lucsok directly beneficially owns 40,856 shares of Common Stock.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions related to executive compensation, which are neither inherently positive nor negative for the company's fundamental outlook.

Positives

• The grant of 7,500 Restricted Stock Award shares to the Chief Operating Officer aligns management incentives with long-term shareholder interests.
• The four-year vesting schedule for the restricted stock award promotes executive retention and encourages sustained performance.

Future Outlook

The 7,500 Restricted Stock Award shares granted to the COO will vest equally on an annual basis over a four-year period, beginning one year from the grant date of July 27, 2025.

Industry Context

This is a routine insider transaction report (Form 4) for a publicly traded company, reflecting standard compensation practices involving equity awards for executives. Such filings are common across all industries and provide transparency into executive stock ownership and activity.

Comparison to Industry Standards

• Equity compensation, particularly through restricted stock awards, is a common practice for executive remuneration across various industries, including healthcare technology, to align management incentives with long-term company performance.
• The vesting schedule of four years for the restricted stock award is typical for such awards, comparable to practices at companies like Medtronic or Stryker, which also utilize long-term incentive plans to retain key talent and encourage sustained growth.
• The tax withholding mechanism for the net settlement of equity awards is a standard procedure across the industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor positive impact as executive incentives are aligned with long-term performance through equity awards.
• Management: The COO's compensation structure is enhanced, providing long-term incentives and retention.

Next Steps

• The 7,500 Restricted Stock Award shares will begin vesting one year from the grant date of July 27, 2025, and continue annually for four years.

Key Dates

Keywords

ZYNEX, ZYXI, Restricted Stock Award, RSA, Insider Transaction, Form 4, Executive Compensation, Stock Incentive Plan, Chief Operating Officer, Equity Compensation